Filter
61
Text search:
Comirnaty
Featured
Recommendations
13
Language
Document type
Guidelines
25
Fact sheets
21
Studies & Reports
5
Manuals
3
Online Courses
3
Infographics
2
Training Material
1
Strategic & Response Plan
1
Countries / Regions
Germany
10
Ukraine
7
Argentina
6
Russia
5
Brazil
4
China
3
Middle East and North Africa
3
South Africa
2
Ecuador
2
Eastern Europe
2
Western and Central Europe
1
Paraguay
1
Kazakhstan
1
Belarus
1
Authors & Publishers
Publication Years
Category
Countries
31
Clinical Guidelines
1
Key Resources
1
Pharmacy & Technologies
1
Toolboxes
COVID-19
45
Refugee
9
Conflict
1
Wird ständig aktualisiert
This document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and infection prevention and control (IPC) measures for the management of possible and confirmed cases of COVID-1
...
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian
...
8 March 2022
A very large number of people from Ukraine are fleeing the country and entering the European Union (EU) countries bordering Ukraine (Hungary, Poland, Romania, Slovakia) and the EU-neighbourhood country of the Republic of Moldova. Those fleeing Ukraine - mainly women and children - are
...
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2,
...
Weekly epidemiological update on COVID-19, 28 September 2022
Empfehlungen des Robert Koch-Instituts für Alten- und Pflegeeinrichtungen und Einrichtungen für Menschen mit Beeinträchtigungen und Behinderungen und für den öffentlichen Gesundheitsdienst
Stand 7.4.2021
A rapid evidence briefing. Vaccinated people are less likely to develop long COVID, even if they get infected, a rapid review of 15 studies by the UK Health Security Agency shows.
COVID-19 & Vaccination
recommended
Issue Brief no.8. January 18,2021
Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies,
...
El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
This training module is designed to equip HWs with knowledge and communication skills to build their confidence and support them in their ability to promote acceptance of COVID-19 vaccination among other HWs.
Covid-19 Epidemiological Surveillance Guide: Public Health Emergency of National Importance for Coronavirus Disease 2019 - version 4
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de
...
interim guidance, 19 July 2021 (arabic version)
Campaña Nacional de Vacunación contra la COVID-19
(Last Update: July 2022)
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan
...
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
